Pernix Therapeutics Announces FDA Acceptance With Priority Review of Its TREXIMET® sNDA for Use in Adolescent Patients
CORRECTING and REPLACING Pernix Therapeutics Exceeds 2014 Revenue Guidance: Delivers FY2014 Net Revenue In Excess of $120 Million
XenoPort Provides Highlights of HORIZANT Prescription Trends and Update on Development for Alcohol Use Disorder
U.S. Food and Drug Administration Approves KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation
Think big if you're serious about investing in virtual fun and games.